Status:
COMPLETED
Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
Lead Sponsor:
Tanabe Pharma Corporation
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
20-64 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety/tolerability and to explore the efficacy of MT-1303 in subjects with systemic lupus erythematosus
Eligibility Criteria
Inclusion
- Diagnosis of SLE based on the American College of Rheumatology (ACR) criteria
- Presence of at least one of the following items: positive anti ds-DNA antibodies, low complement levels, and so on.
- Stable doses of corticosteroids
Exclusion
- Severe active lupus nephritis, neuropsychiatric SLE
Key Trial Info
Start Date :
February 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2017
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT02307643
Start Date
February 1 2015
End Date
May 1 2017
Last Update
June 14 2017
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Inverstigational site
Bunkyō City, Japan
2
Inverstigational site
Chiba, Japan
3
Inverstigational site
Chūōku, Japan
4
Inverstigational site
Fuchu-shi, Japan